Ameluz for Actinic Keratoses
Ameluz for Actinic Keratoses
December 5, 2016 (Issue: 1509)
The FDA has approved a 10% nanoemulsion gel
formulation of the porphyrin-based photosensitizer
aminolevulinic acid hydrochloride (ALA; Ameluz –
Biofrontera) for use in combination with a narrowband
red light photodynamic therapy (PDT) lamp...more
- New treatments for actinic keratoses. Med Lett Drugs Ther 2002; 44:57.
- JA Siegel et al. Current perspective on actinic keratosis: a review. Br J Dermatol 2016 August 8 (epub).
- B Berman et al. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother 2009; 10:3015.
- Ingenol mebutate (Picato) for actinic keratoses. Med Lett Drugs Ther 2012; 54:35.
- FDA Drug Safety Communication: FDA warns of severe adverse events with application of Picato (ingenol mebutate) gel for skin conditions requires label changes. Available at: www.fda.gov. Accessed November 22, 2016.
- RM Szeimies et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol 2010; 163:386.
- T Dirschka et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. Br J Dermatol 2012; 166:137.
- U Reinhold et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED® lamp. Br J Dermatol 2016; 175:696.
- T Dirschka et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. Br J Dermatol 2013; 168:825.
- AK Gupta and M Paquet. Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169:250.
- S Vegter and K Tolley. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One 2014; 9:e96829.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Ameluz for Actinic Keratoses
Article code: 1509c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
